Trial
NCT01582009
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
Novartis
Condition
Clear Cell Renal Cell Carcinoma
Intervention
panobinostat
Why stopped
pts off study, PI left institute
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-08-15